For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0800) 17 37Belgium
(+32) 3 286 69 80Switzerland
(+41) 43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (020) 348 80 00United Kingdom
+44 20 3636 9400United States of America
+1 212 376 0134Joint Global Coordinator & Joint Bookrunner
Kempen & Co Deal Alert | Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 170m Capital Increase
Xbrane is a Swedish biosimilar developer with a proprietary manufacturing platform. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference products. Lead candidate Ximluci®, a biosimilar candidate to VEGF inhibitor Lucentis®, is under registration in Europe with a planned launch with STADA during the first quarter of 2023 and an envisaged US launch with BAUSCH + Lomb for the end of 2023
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: